MedTrace Logo

Modafinil Treatment for Sleep/Wake Disturbances in Older Adults

NCT00626210 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2019-10-28

Study results available
· View outcomes & findings →

Summary

Modafinil, trade named Provigil, is a medication approved by the Food and Drug Administration for the treatment of narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder. Each of these problems is characterized by difficulty sleeping at night and excessive daytime sleepiness. Modafinil is prescribed during the day to counteract this sleepiness. The idea behind this treatment is that sleepiness that leads to napping during the day prevents a patient from being tired or sleepy enough to get good sleep at night. This study is designed to determine if the medication can "reset" participants' sleep/wake rhythm to a more normal rhythm.

Conditions

  • Insomnia
  • Sleep Initiation and Maintenance Disorders
  • Alzheimer Disease

Interventions

DRUG

modafinil

100-400 mg daily for 4 weeks

Sponsors & Collaborators

  • VA Palo Alto Health Care System

    lead FED

Principal Investigators

  • Jamie M Zeitzer, PhD · Stanford University/VAPAHCS

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2011-04-30
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00626210 on ClinicalTrials.gov